EUVIMEDEUVIMED entdecken
Crossref

Treatment consensus for locally advanced cervical cancer

Ping Jiang, Zhuhui Yuan, Lichun Wei, Fengju Zhao, Xiangkun Yuan, Yipeng Song, Jing Bai, Xiaofan Li, Baosheng Sun, Lijuan Zou, Sha Li, Yuhua Gao und 8 weitere

Advances in Radiotherapy & Nuclear Medicine · 2025

DOI: 10.36922/arnm.4032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2025. Verfasst von Ping Jiang und 19 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Concurrent chemoradiotherapy (CCRT) involves the simultaneous administration of chemotherapy and radiotherapy, in which low-dose chemotherapy enhances the effectiveness of radiotherapy. This combined approach mitigates tumor recurrence and metastasis, ultimately improving patient prognosis. The primary mechanism behind the increased radiosensitivity induced by concurrent chemotherapy involves inhibiting tumor cell repair and the complementary effects of chemotherapy and radiotherapy on different phases of the cell cycle. Despite CCRT application in patients with locally advanced cervical cancer (LACC), the 5-year survival rate remains at 60%. To improve treatment efficacy, a series of exploratory investigations have been conducted, encompassing the integration of targeted therapy, immunotherapy, and utilization of immunomodulatory agents in neoadjuvant protocols preceding CCRT. Although targeted therapies and immunomodulators represent efficacious interventions for LACC management, the scarcity of robust, large-scale evidence-based data necessitates the undertaking of multicenter prospective randomized Phase III clinical trials and dissemination of high-quality publications to elevate the standard of evidence-based medicine. This consensus acts as a valuable resource for clinicians and researchers, highlighting recent seminal evidence-based studies and the evolving landscape of clinical research on targeted and immunomodulatory agents.

Zitieren

APA

Jiang, P., Yuan, Z., Wei, L., Zhao, F., Yuan, X., Song, Y., Bai, J., Li, X., Sun, B., Zou, L., Li, S., Gao, Y., Zhuo, Y., Gao, S., Xu, Q., Zhou, X., Zhu, H., Zhang, Y., Liu, Z., & Wang, J. (2025). Treatment consensus for locally advanced cervical cancer. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.4032

Vancouver

Jiang P, Yuan Z, Wei L, Zhao F, Yuan X, Song Y, et al. Treatment consensus for locally advanced cervical cancer. Advances in Radiotherapy & Nuclear Medicine. 2025. doi:10.36922/arnm.4032

BibTeX
@article{Jiang2025,
  author = {Jiang, Ping and Yuan, Zhuhui and Wei, Lichun and Zhao, Fengju and Yuan, Xiangkun and Song, Yipeng and Bai, Jing and Li, Xiaofan and Sun, Baosheng and Zou, Lijuan and Li, Sha and Gao, Yuhua and Zhuo, Yanhong and Gao, Song and Xu, Qin and Zhou, Xiaohong and Zhu, Hong and Zhang, Yunyan and Liu, Zi and Wang, Junjie},
  title = {Treatment consensus for locally advanced cervical cancer},
  journal = {Advances in Radiotherapy & Nuclear Medicine},
  year = {2025},
  doi = {10.36922/arnm.4032}
}
Kostenlos starten →